Browse the evidence

Selective reduction of ~800 kcal/d of dietary fat results in no change in the 24 hr RQ or fat oxidation rate.

Reducing fat intake alone may not affect metabolic rates or fat oxidation.

Two-thirds of adults are either overweight or obese.

Addressing obesity should be a priority in public health initiatives.

The cost-effectiveness of ILI over the 9-year period is unclear due to different health utility measures leading to different conclusions.

Practitioners should be cautious in interpreting the cost-effectiveness of lifestyle interventions due to variability in health utility measures.

Differences in fat availability and utilization during steady-state exercise had little effect on the time taken to complete a 600 kJ time-trial.

Fat availability may not influence performance in short-duration high-intensity efforts.

Body composition changes did not differ significantly by dietary fat or glycemic index.

This suggests that dietary fat and glycemic index may not be critical factors in body composition changes during weight loss.

There are three broadly different subtypes of vegan diets: vegan (general), raw food vegan, and whole food vegan.

Understanding the different subtypes of vegan diets can help practitioners tailor dietary advice.

Neither High Quality nor High Adherence alone were significantly different than the Low Quality/Low Adherence subgroups.

Focus on both dietary quality and adherence rather than either alone for weight loss strategies.

In China, there was no significant association between white rice intake and diabetes risk (HR: 1.05; 95% CI: 0.78-1.41, p for trend = 0.38).

Dietary recommendations regarding white rice may differ in China compared to other regions due to the lack of associated diabetes risk.

Weight loss magnitude was lower in patients taking GLP-1 RAs compared to postbariatric patients (29.9 kg vs 47.2 kg).

Understanding the differences in weight loss can help tailor interventions for patients seeking body contouring.

Systematic measurement of sexual desire should be prioritized in future research on GLP-1 agonists.

Researchers should include sexual desire as a key outcome in studies involving GLP-1 agonists.

Gastrointestinal complaints were common but did not significantly influence satisfaction ratings or decisions to continue treatment.

Practitioners should note that while gastrointestinal side effects are common, they may not deter patients from continuing treatment if weight loss is achieved.

A modified prolactin-releasing peptide, NN501, reduces body weight primarily through sustained fatty acid oxidation rather than hypophagia.

NN501 may be a viable alternative therapy for obesity management focusing on fatty acid oxidation.

Discontinuation rates for GLP-1 RAs can be up to 80% after 2 years.

Practitioners should be aware of high discontinuation rates when prescribing GLP-1 RAs.

LLM responses provided appropriate information about standard GLP1RA-related queries but lacked updated information on emerging concerns.

Practitioners should be aware that while LLMs can provide useful information, they may not reflect the latest developments in GLP1RA therapy.

Internet search responses were more heterogeneous and often commercially biased.

Practitioners should critically evaluate internet sources for GLP1RA information due to potential bias.

Meta-regression showed no significant effect modification by age, body mass index, HbA1c, follow-up duration, or sodium-glucose co-transporter 2 inhibitors use.

The effectiveness of semaglutide is consistent regardless of these common patient characteristics.

There were no significant differences in the amount of weight lost between semaglutide 0.5 mg and liraglutide 3 mg after 3 months.

Clinicians can expect similar weight loss outcomes from either treatment option.

Over half (60%) of participants with a BMI indicating obesity had no clinical diagnosis of obesity in their EHRs.

Clinicians should be aware that a significant number of patients with obesity may not be diagnosed, potentially leading to untreated health issues.

Men, and particularly NH-Asian men, may be at heightened risk of underdiagnosis of obesity.

Awareness of potential underdiagnosis in specific male populations can improve obesity management strategies.

There have been some adjustments in weight reduction medications available on the German market in the last two years.

Stay updated on the latest weight reduction medications available in Germany.

The article provides an outlook on new weight reduction medications that are about to be approved or are currently in Phase 3 of approval studies.

Be aware of new medications that may soon be available for weight reduction.

There are challenges to the use of GLP-1 RAs, including drug expense and availability.

Healthcare providers should be aware of the barriers to access when prescribing GLP-1 RAs.

The article provides an overview of available GLP-1 RAs, their mechanisms of action, indications, adverse reactions, and risks.

Providers can refer to this overview for practical information on GLP-1 RAs.

NHB participants reported higher perceived discrimination, sleep disturbance, and perceived stress than H and NHW participants at all time points.

Addressing psychosocial factors is crucial for improving surgical outcomes in NHB patients.